Trichostatin A promotes GLI1 degradation and P21 expression in multiple myeloma cells

Abstract

BackgroundHistone deacetylase inhibitors are promising drugs for the future application in cancer therapy. Trichostatin A (TSA), a histone deacetylase inhibitor, exhibits effective antitumor effects in various cancers. However, the effects and underlying mechanisms of TSA on multiple myeloma (MM) are not fully investigated.MethodsIn the present study, RPMI8226 and MM.1S cells treated with TSA were used for cell proliferation, cell cycle, and survival examinations, then the localization and post transcriptional modification of GLI1 protein as well as the target gene P21 were analyzed using immunofluorescence, immunoprecipitation, western blots and qPCR, respectively.ResultsTSA exerted a time and dose-dependent cytotoxicity on MM cell lines, and suppressed the proliferation of MM cells and induced an upregulation of p21 protein accompanied by a decreased expression of cyclin D1. TSA treatment led to a downregulation of GLI1, and the nuclear accumulation of GLI1 was also inhibited. As a result of hedgehog inhibition, the expression of MYC and SURVIVIN was greatly weakened after TSA treatment. Furthermore, TSA accelerated GLI1 degradation in a proteasome-dependent manner. Additionally, p21 induction also contributed to GLI1 downregulation via reducing the transcription of GLI in mRNA level. Rescue experiments verified that exogenous expression of GLI1 alleviated MM cell apoptosis induced by TSA.ConclusionThese results indicated that TSA represses MM cell growth and induces cell apoptosis. The inhibition of hedgehog signaling is an important mechanism accounting for the cytotoxic effects of TSA.

Non-canonical Hedgehog Signaling Pathway in Cancer: Activation of GLI Transcription Factors Beyond Smoothened

“…Remarkably, HDAC6 effects seem to be independent of GLI acetylation, and to occur most likely through the transcriptional control of GLI2 expression and stabilization of GLI3 protein (Dhanyamraju et al, 2015). In line with these findings, a recent study in multiple myeloma revealed that hyper-acetylation of GLI1 through pharmacological inhibition of class I and II HDACs leads to reduced tumor survival by decreasing nuclear accumulation and transcriptional activity of GLI1, and accelerating its proteasomal degradation (Geng et al, 2018).…”

Using Prognosis-Related Gene Expression Signature and Connectivity Map for Personalized Drug Repositioning in Multiple Myeloma

“…The treatment of trichostatin A in MM cells led to alterations in H3K4 methylation [21]. After treatment with trichostatin A, the proliferation inhibition of MM cells was found via GLI1 degradation and P21 overexpression, and this proliferation inhibitory effect had a time- and dose-dependent character [22]. The result of the molecular docking between trichostatin A and CDK1 may reveal a new mechanism for the action of trichostatin A in MM.…”

Physalin B attenuates liver fibrosis via suppressing LAP2α–HDAC1‐mediated deacetylation of the transcription factor GLI1 and hepatic stellate cell activation

“…Among the HDACs, HDAC1 is a positive modulator of activator members of the GLI family (Canettieri et al, 2010). GLI1 physically interacts with HDAC1, and HDAC1‐mediated deacetylation of GLI1 results in its transcriptional activity (Canettieri et al, 2010; Falkenberg et al, 2016; Geng et al, 2018; Gurung et al, 2013). GLI1 deacetylation leads to the growth of medulloblastoma (Canettieri et al, 2010) and is increased in resistant basal cell carcinomas (Mirza et al, 2019).…”